PT - JOURNAL ARTICLE AU - Leon-Abarca, Juan A. AU - Memon, Roha S. AU - Rehan, Bahar AU - Iftikhar, Maimoona AU - Chatterjee, Antara TI - The impact of COVID-19 in diabetic kidney disease and chronic kidney disease: A population-based study AID - 10.1101/2020.09.12.20193235 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.12.20193235 4099 - http://medrxiv.org/content/early/2020/09/16/2020.09.12.20193235.short 4100 - http://medrxiv.org/content/early/2020/09/16/2020.09.12.20193235.full AB - Background The spectrum of pre-existing renal disease is known as a risk factor for severe COVID-19 outcomes. However, little is known about the impact of COVID-19 on patients with diabetic nephropathy in comparison to patients with chronic kidney disease.Methods We used the Mexican Open Registry of COVID-19 patients 11 to analyze anonymized records of those who had symptoms related to COVID-19 to analyze the rates of SARS-CoV-2 infection, development of COVID-19 pneumonia, admission, intubation, Intensive Care Unit admission and mortality. Robust Poisson regression was used to relate sex and age to each of the six outcomes and find adjusted prevalences and adjusted prevalence ratios. Also, binomial regression models were performed for those outcomes that had significant results to generate probability plots to perform a fine analysis of the results obtained along age as a continuous variable.Results The adjusted prevalence analysis revealed that that there was a a 87.9% excess probability of developing COVID-19 pneumonia in patients with diabetic nephropathy, a 5% excess probability of being admitted, a 101.7% excess probability of intubation and a 20.8% excess probability of a fatal outcome due to COVID-19 pneumonia in comparison to CKD patients (p< 0.01).Conclusions Patients with diabetic nephropathy had nearly a twofold rate of COVID-19 pneumonia, a higher probability of admission, a twofold probability of intubation and a higher chance of death once admitted compared to patients with chronic kidney disease alone. Also, both diseases had higher COVID-19 pneumonia rates, intubation rates and case-fatality rates compared to the overall population.Competing Interest StatementThe authors have declared no competing interest.Funding Statementhttps://www.gob.mx/salud/documentos/datos-abiertos-152127Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As a secondary analysis this manuscript was exempt of IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesProcessed data files used in the present study are available at request. The authors follow the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement for data collection, analysis and reporting of results.